Physician

Adam M Brufsky, MD

According to 2025 Medicare claims, Adam Brufsky, MD (NPI: 1518939537) practices medical oncology in the Pittsburgh, PA market, with the plurality of this provider's patient population coming from Allegheny, PA. This provider's primary affiliated billing organization is UNIVERSITY OF PITTSBURGH PHYSICIANS (NPI: 1407804057; TIN: 232919472) and primary practice location at 15213-3108.

Brufsky's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 190 traditional Medicare patients, billed 395 HCPCS/CPT codes, and received $26,944 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,196 prescription claims across 247 beneficiaries totaling $2,144,823 in drug costs, led by Ibrance (Palbociclib). DME data shows 46 claims. Open Payments data shows 295 records totaling $963,885. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $0 to $1,594.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	177	380	$22,282
2016	185	367	$20,871
2017	269	650	$37,732
2018	230	563	$31,503
2019	229	541	$32,464
2020	203	461	$27,684
2021	192	507	$39,791
2022	216	496	$38,839
2023	202	476	$34,776
2024	190	395	$26,944

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	245	1,214	$669,258
2016	262	1,248	$1,169,189
2017	297	1,398	$2,079,175
2018	297	1,469	$2,139,643
2019	314	1,612	$3,273,489
2020	292	1,621	$3,289,222
2021	296	1,434	$2,062,497
2022	279	1,256	$1,502,513
2023	272	1,198	$1,750,792
2024	247	1,196	$2,144,823

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	14	17	$1,965
2016	11	13	$1,134
2017	11	61	$14,861
2018	N/R	45	$7,994
2019	N/R	96	$11,774
2020	N/R	23	$2,354
2021	11	25	$2,106
2022	30	35	$5,129
2023	19	44	$9,976
2024	14	46	$3,811

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	11	11	$137
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	30	62	$105
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	121	222	$65
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	63	69	$40

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	59	1,764	$1,002,122
Orserdu	Elacestrant Hcl	16	480	$370,714
Verzenio	Abemaciclib	21	588	$221,796
Anastrozole	Anastrozole	394	29,597	$7,415
Exemestane	Exemestane	62	3,480	$4,441

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	14	22	$2,521
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	13	$959
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$331

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	224	$326,259	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	71	$637,627	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam M. Brufsky, MD?

Tedicare shows public-source Medicare data for Adam M. Brufsky, MD (NPI 1518939537), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam M. Brufsky, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adam M. Brufsky, MD?

Adam M. Brufsky, MD is linked to UNIVERSITY OF PITTSBURGH PHYSICIANS (billing NPI 1407804057) in the available physician profile data.

Does Adam M. Brufsky, MD have Open Payments data?

Adam M. Brufsky, MD has 295 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.